Imamoglu M Abdurrahim, Tuygun Can, Bakirtas Hasan, Yiğitbasi Orhan, Kiper Ahmet
Department of Urology, SSK Ankara Education Hospital, Ankara, Turkey.
Eur Urol. 2005 Feb;47(2):209-13. doi: 10.1016/j.eururo.2004.08.019.
To compare the effectiveness of macroplastique injection with artificial urinary sphincter implantation (AUS) for treatment of postprostatectomy incontinence (PPI).
A prospective randomized clinical trial including 45 patients with PPI was performed secondary to radical retropubic prostatectomy (RRP), transvesical prostatectomy (TVP), transurethral prostatectomy (TURP), and TURP with TVP, in 12, 16, 16, 1 patients respectively. Patients were divided into two groups as minimal (group I) and total incontinence (group II) according to the severity of incontinence. Respectively, Group I (n = 21) and group II (n = 24) patients were randomized as AUS implantation (n = 11, n = 11) and macroplastique injection (n = 10, n = 13). Follow-up period was 48 (6-84) months in patients with macroplastique injection and 60 (8-120) months in AUS implantation. The success of the treatment was evaluated by calculating the average number of pads used by the patient per day, the weight of the pads and score of quality of life survey scale for each group both in the preoperative and in the postoperative period.
There were statistically significant differences between preoperative and postoperative average pad weight, average number of pads and quality of life scores, both in patients with minimal and total incontinence. In group I there was no statistically significant difference between the two techniques. However, in group II there was a significant difference favoring AUS implantation.
Endourethral injection should be the treatment of choice for patients with minimal incontinence, whereas AUS implantation as the first choice for patients with total incontinence.
比较注射Macroplastique与植入人工尿道括约肌(AUS)治疗前列腺切除术后尿失禁(PPI)的疗效。
进行一项前瞻性随机临床试验,纳入45例PPI患者,这些患者分别因耻骨后根治性前列腺切除术(RRP)、经膀胱前列腺切除术(TVP)、经尿道前列腺切除术(TURP)以及TURP联合TVP手术导致PPI,各手术方式导致的患者数分别为12例、16例、16例、1例。根据尿失禁严重程度将患者分为轻度(I组)和完全失禁(II组)两组。I组(n = 21)和II组(n = 24)患者分别随机分为AUS植入组(n = 11,n = 11)和注射Macroplastique组(n = 10,n = 13)。注射Macroplastique组患者的随访期为48(6 - 84)个月,AUS植入组为60(8 - 120)个月。通过计算术前和术后每组患者每天使用尿垫的平均数量、尿垫重量以及生活质量调查量表评分来评估治疗效果。
轻度和完全失禁患者术前和术后的平均尿垫重量、平均尿垫数量及生活质量评分均有统计学显著差异。在I组中,两种技术之间无统计学显著差异。然而,在II组中,AUS植入组有显著优势。
尿道内注射应作为轻度尿失禁患者的首选治疗方法,而AUS植入则是完全失禁患者的首选。